You can find the annual or quarterly income statement of Tarsus Pharmaceuticals Inc here for insights into the performance and operational efficiency of Tarsus Pharmaceuticals Inc.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q2

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2020Q3

Total revenue

69.41%173.91M

106.87%162.05M

128.39%151.67M

146.68%118.70M

151.54%102.66M

183.68%78.33M

407.86%66.41M

2471.78%48.12M

--40.81M

1004.56%27.61M

30.76%13.08M

--1.87M

-100.00%0.00

363.82%2.50M

2858.58%10.00M

-100.00%0.00

-30.61%15.28M

-98.39%539.00K

--338.00K

--1.24M

--22.02M

--33.43M

----

Revenue

69.41%173.91M

106.87%162.05M

128.39%151.67M

146.68%118.70M

151.54%102.66M

183.68%78.33M

407.86%66.41M

2471.78%48.12M

--40.81M

1004.56%27.61M

30.76%13.08M

--1.87M

-100.00%0.00

363.82%2.50M

2858.58%10.00M

-100.00%0.00

-30.61%15.28M

-98.39%539.00K

--338.00K

--1.24M

--22.02M

--33.43M

----

Cost of revenue

94.21%12.11M

80.31%9.40M

121.82%10.93M

156.29%8.31M

107.62%6.24M

215.05%5.21M

305.10%4.93M

759.95%3.24M

--3.00M

--1.65M

204.00%1.22M

--377.00K

-100.00%0.00

1766.67%400.00K

-100.00%0.00

-29.17%522.00K

-97.46%33.00K

---24.00K

--65.00K

--737.00K

--1.30M

----

Operating expenses

55.25%193.82M

60.76%168.18M

75.76%159.64M

81.80%133.23M

68.45%124.84M

60.21%104.61M

57.89%90.83M

71.19%73.28M

125.82%74.11M

137.86%65.30M

129.54%57.53M

86.88%42.81M

60.09%32.82M

36.85%27.45M

69.49%25.06M

35.18%22.91M

39.13%20.50M

-11.70%20.06M

28.83%14.79M

67.09%16.95M

--14.73M

--22.72M

--11.48M

--10.14M

R&D expenses

98.86%31.01M

55.12%22.35M

6.89%18.04M

34.27%16.28M

26.58%15.59M

19.42%14.41M

26.82%16.87M

0.19%12.13M

-1.81%12.32M

-2.35%12.07M

32.68%13.30M

10.93%12.11M

30.65%12.55M

2.28%12.36M

24.76%10.03M

6.89%10.91M

33.30%9.60M

-25.71%12.08M

5.94%8.04M

27.76%10.21M

--7.20M

--16.26M

--7.59M

--7.99M

Depreciation, depletion, and amortization

----

-4.35%440.00K

0.68%443.00K

53.33%460.00K

89.54%453.00K

70.37%460.00K

26.80%440.00K

22.95%300.00K

31.32%239.00K

159.62%270.00K

254.08%347.00K

159.57%244.00K

97.83%182.00K

153.66%104.00K

145.00%98.00K

-6.00%94.00K

-26.40%92.00K

-35.94%41.00K

-9.09%40.00K

316.67%100.00K

--125.00K

--64.00K

--44.00K

--24.00K

Other operating expenses

----

---196.00K

----

Operating profit

10.26%-19.91M

76.70%-6.12M

67.34%-7.98M

42.26%-14.53M

33.39%-22.18M

30.26%-26.28M

45.06%-24.42M

38.53%-25.16M

-1.47%-33.30M

-51.03%-37.68M

-195.13%-44.45M

-78.71%-40.94M

-528.27%-32.82M

-27.82%-24.95M

-4.24%-15.06M

-45.85%-22.91M

-171.74%-5.22M

-282.20%-19.52M

-25.89%-14.45M

-54.87%-15.71M

--7.28M

--10.71M

---11.48M

---10.14M

Net non-operating interest income (expenses)

Non-operating interest income

-12.56%3.70M

7.76%3.72M

8.31%3.95M

-0.15%4.11M

2.40%4.23M

10.81%3.45M

22.46%3.65M

45.07%4.12M

85.53%4.13M

35.94%3.12M

40.01%2.98M

167.67%2.84M

--2.23M

--2.29M

--2.13M

--1.06M

----

Non-operating interest expense

2.96%2.16M

-5.06%1.97M

-5.34%2.06M

-8.64%2.12M

4.28%2.09M

138.67%2.07M

147.61%2.17M

205.94%2.32M

146.38%2.01M

27.05%869.00K

26.88%878.00K

19.59%757.00K

--815.00K

--684.00K

--692.00K

--633.00K

----

Gains from sale of securities

2026.03%2.81M

-14.39%-159.00K

-13.04%-156.00K

-17.83%-152.00K

-44.55%-146.00K

-21.93%-139.00K

-24.32%-138.00K

-27.72%-129.00K

---101.00K

---114.00K

---111.00K

---101.00K

----

Special income (expenses)

----

--0.00

100.00%0.00

----

-100.00%0.00

100.00%0.00

-6009.09%-1.95M

-858.54%-786.00K

642.86%572.00K

-374.19%-147.00K

108.73%33.00K

81.24%-82.00K

121.63%77.00K

91.04%-31.00K

56.85%-378.00K

---437.00K

---356.00K

---346.00K

---876.00K

----

--0.00

Other non-operating income (expenses)

-93.79%-281.00K

-7.41%-87.00K

-174.07%-74.00K

46.27%98.00K

-145.76%-145.00K

-113.39%-81.00K

-107.69%-27.00K

239.58%67.00K

-25.53%-59.00K

9983.33%605.00K

74.00%-13.00K

-585.71%-48.00K

-144.34%-47.00K

-83.78%6.00K

-900.00%-50.00K

-240.00%-7.00K

371.79%106.00K

208.82%37.00K

---5.00K

--5.00K

---39.00K

---34.00K

----

Income before tax

----

81.63%-4.62M

72.68%-6.31M

46.26%-12.59M

38.90%-20.34M

29.70%-25.12M

44.84%-23.11M

40.18%-23.42M

-5.94%-33.29M

-52.57%-35.73M

-208.13%-41.90M

-73.87%-39.15M

-447.17%-31.42M

-15.72%-23.42M

8.10%-13.60M

-40.39%-22.52M

-190.10%-5.74M

-289.33%-20.24M

-29.04%-14.80M

-58.21%-16.04M

--6.37M

--10.69M

---11.47M

---10.14M

Income tax

--2.72M

--2.35M

--2.06M

----

--0.00

100.00%0.00

--0.00

-100.00%0.00

98.53%-5.00K

-100.00%0.00

-99.68%1.00K

--54.00K

-34200.00%-341.00K

--29.00K

--313.00K

--0.00

--1.00K

Income after tax

----

72.27%-6.97M

63.77%-8.37M

46.26%-12.59M

38.90%-20.34M

29.70%-25.12M

44.84%-23.11M

40.18%-23.42M

-5.94%-33.29M

-52.57%-35.73M

-208.13%-41.90M

-73.91%-39.15M

-447.17%-31.42M

-15.72%-23.42M

8.43%-13.60M

-43.41%-22.51M

-190.51%-5.74M

-295.05%-20.24M

-29.51%-14.85M

-54.83%-15.70M

--6.34M

--10.38M

---11.47M

---10.14M

Net income from continuous operations

----

72.27%-6.97M

63.77%-8.37M

46.26%-12.59M

38.90%-20.34M

29.70%-25.12M

44.84%-23.11M

40.18%-23.42M

-5.94%-33.29M

-52.57%-35.73M

-208.13%-41.90M

-73.91%-39.15M

-447.17%-31.42M

-15.72%-23.42M

8.43%-13.60M

-43.41%-22.51M

-190.51%-5.74M

-295.05%-20.24M

-29.51%-14.85M

-54.83%-15.70M

--6.34M

--10.38M

---11.47M

---10.14M

Net income attributable to controlling interests

----

72.27%-6.97M

63.77%-8.37M

46.26%-12.59M

38.90%-20.34M

29.70%-25.12M

44.84%-23.11M

40.18%-23.42M

-5.94%-33.29M

-52.57%-35.73M

-208.13%-41.90M

-73.91%-39.15M

-447.17%-31.42M

-15.72%-23.42M

8.39%-13.60M

-43.41%-22.51M

-191.17%-5.74M

-296.75%-20.24M

-29.45%-14.84M

-54.83%-15.70M

--6.30M

--10.29M

---11.47M

---10.14M

Net income attributable to common shareholders

----

72.27%-6.97M

63.77%-8.37M

46.26%-12.59M

38.90%-20.34M

29.70%-25.12M

44.84%-23.11M

40.18%-23.42M

-5.94%-33.29M

-52.57%-35.73M

-208.13%-41.90M

-73.91%-39.15M

-447.17%-31.42M

-15.72%-23.42M

8.39%-13.60M

-43.41%-22.51M

-191.17%-5.74M

-296.75%-20.24M

-29.45%-14.84M

-54.83%-15.70M

--6.30M

--10.29M

---11.47M

---10.14M

Basic earnings per share

10.45%-0.43

74.60%-0.16

67.34%-0.20

51.59%-0.30

45.45%-0.48

36.92%-0.64

52.31%-0.60

52.27%-0.61

24.89%-0.88

-15.58%-1.01

-146.86%-1.26

-51.42%-1.28

-396.50%-1.17

10.38%-0.88

29.06%-0.51

-11.02%-0.84

-177.02%-0.24

-293.20%-0.98

-28.34%-0.72

-40.72%-0.76

--0.31

--0.51

---0.56

---0.54

Diluted earnings per share

10.45%-0.43

74.60%-0.16

67.34%-0.20

51.59%-0.30

45.45%-0.48

36.92%-0.64

52.31%-0.60

52.27%-0.61

24.89%-0.88

-15.58%-1.01

-146.86%-1.26

-51.42%-1.28

-396.50%-1.17

10.38%-0.88

29.06%-0.51

-11.02%-0.84

-182.27%-0.24

-307.22%-0.98

-28.34%-0.72

-40.72%-0.76

--0.29

--0.47

---0.56

---0.54

Dividend per share

----

--0.00

Currency unit

--USD

Audit opinions

----

FAQs

How do I read Tarsus Pharmaceuticals Inc's income statement on TradingKey?



Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?



A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?



YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing TARS stock?



Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Tarsus Pharmaceuticals Inc's revenue at year end?



Tarsus Pharmaceuticals Inc reported 451.36M in revenue for fiscal year 2025, up from 182.95M in the previous year.

How much revenue did Tarsus Pharmaceuticals Inc report in the most recent quarter?



Tarsus Pharmaceuticals Inc reported 173.91M in revenue for the most recent quarter, an increase of 69.41% year over year.

What was Tarsus Pharmaceuticals Inc's net income for the year?



Tarsus Pharmaceuticals Inc posted -66.42M in net income for fiscal year 2025.

What was Tarsus Pharmaceuticals Inc's annual operating profit?



Tarsus Pharmaceuticals Inc's operating income was -70.97M for fiscal year 2025.

How is EPS related to the income statement?



EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.